The increasing use of anthracyclines, together with the longer survival of cancer patients, means the toxic effects of these drugs need to be monitored. In order to detect, prevent or mitigate anthracycline-induced cardiomyopathy, it is essential that all patients undergo a rigorous initial cardiovascular assessment, followed by close monitoring. Several clinical trials have shown the cardioprotective effect of non-pharmacological measures such as exercise, healthy lifestyles, control of risk factors and treatment of comorbidities; a cardioprotective effect has also been observed with pharmacological measures such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, statins, dexrazoxane and liposomal formulations. However, there are currently no guidelines for managing prevention in these patients. In this review the authors discuss the state of the art of the assessment, monitoring, and, above all, the prevention of anthracycline-induced cardiotoxicity.
Introduction
According to the World Health Organization, cancer is the second leading cause of death worldwide. 1 The considerable and ongoing advances in treatment have increased survival of cancer patients, but the adverse effects of chemotherapy, particularly on the heart, are a significant cause of mortality and morbidity. Mortality among cancer patients who develop anthracycline-induced cardiomyopathy is high (over 60% at two years), 2 but prognosis can be improved by early detection and prevention.
Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin are the most commonly used chemotherapy drugs in cancer. They are a known cause of cardiotoxicity (Table 1) , with acute or/and subacute effects that can manifest as electrocardiographic changes, ventricular and supraventricular arrhythmias, cardiac conduction disturbances (atrioventricular or branch block), ventricular dysfunction, rises in brain-type natriuretic peptide (BNP, a marker of increased preload and heart failure [HF]), myocarditis and pericarditis, and that may occur at any time between beginning of treatment and two weeks after the end of treatment. These effects are relatively uncommon and most revert a week after treatment cessation. Chronic cardiomyopathy is defined as early if it begins within a year of ending chemotherapy and late after that period. In either case, systolic or diastolic dysfunction are observed ( Table 2 ) that can progress to severe cardiomyopathy and may even lead to death. 3 Although some studies have suggested that the risk of developing ventricular dysfunction and its severity can be predicted on the basis of acute myocardial injury, 4 the relationship between acute and chronic toxicity is not fully understood. Diagnosis of cardiac dysfunction induced by cancer therapy has been the subject of various studies, 3, 5 one of which 5 is considered the reference publication on the subject, and is based on HF symptoms, physical examination and parameters of left ventricular function.
One proposed classification divides chemotherapyinduced cardiomyopathy into two types: type I, caused by anthracyclines, which induce irreversible dose-dependent cardiac injury; and type II, caused by trastuzumab, which is not related to the cumulative dose and is often reversible after treatment discontinuation. 6 The second type will not be discussed in this review article.
In this review the authors discuss strategies in patients being treated with anthracyclines in order to prevent or mitigate their main adverse effects on the heart.
Initial assessment
In view of the cardiotoxicity of anthracyclines, all patients referred for chemotherapy should undergo a cardiac assessment to establish their baseline cardiovascular characteristics, which can then be used during the treatment regimen for purposes of comparison. This assessment should include clinical history and physical examination, electrocardiography to determine cardiac rhythm and detect signs of ischemia, and cardiac imaging, usually transthoracic echocardiography with complete Doppler study (Tables 3 and 4 ). When the echocardiogram is provides insufficient information, cardiac magnetic resonance imaging (CMRI) is recommended. Baseline troponin levels should also be measured for future comparisons. 5
Monitoring during therapy
It is important to monitor for signs and symptoms of cardiotoxicity during chemotherapy ( Table 5 ). The 12-lead electrocardiogram can be used routinely to screen for arrhythmias due to anthracycline-related cardiotoxicity, while 24-hour Holter monitoring or an event recorder can be useful to investigate the etiology of syncope presumed to result from arrhythmia or advanced atrioventricular block. 7 Cardiac function should be monitored by echocardiography in patients under anthracycline therapy. Global longitudinal strain (GLS) as assessed by two-dimensional speckle tracking is a more sensitive predictor of HF than left ventricular ejection fraction (LVEF), 8 since during anthracycline therapy changes in GLS precede reduction in LVEF. 5 However, in clinical practice, fractional shortening and LVEF have been the most widely used parameters, 9 although fractional shortening is proving to be less reliable in this context. These parameters, being dependent on pre-and afterload, are less sensitive for early detection of preclinical cardiac disease. Various studies have suggested that assessment of diastolic function by Doppler echocardiography may enable early detection of anthracycline-induced cardiomyopathy. 10, 11 If LVEF is <53%, GLS below the limit of normal (Table 6) , and/or Any one of the criteria is sufficient to confirm a diagnosis of cardiac dysfunction. Cardiomyopathy characterized by a decrease in cardiac LVEF that is either global or more severe in the septum Symptoms of CHF Detection of S3 gallop, tachycardia, or both; Decline in LVEF of at least 5% to less than 55% with accompanying signs or symptoms of CHF, or a decline in LVEF of at least 10% to below 55% without accompanying signs or symptoms.
CHF: congestive heart failure; LVEF: left ventricular ejection fraction. Adapted from 3,60 . troponins are elevated, a cardiology consultation should be considered, with discussion between the cardiologist and oncologist of the risk/benefit ratio of chemotherapy. 5 A fall in LVEF during anthracycline therapy is associated with increased risk for cardiac events, and although a reduction in GLS of <8% compared to baseline appears not to be significant, a reduction of >15% is likely to indicate cardiotoxicity. 5 The study should be repeated two to three weeks after the baseline study to confirm the diagnosis. CMRI can detect subtle changes in the myocardium and increases in extracellular volume, which suggest edema or diffuse fibrosis. Although it is highly sensitive and reproducible for assessment of cardiac function and characterization of myocardial tissue, CMRI has the disadvantages of limited availability and high cost. 12 Radionuclide angiography is reproducible and more easily available, but exposes patients to ionizing radiation, increasing their cumulative dose, especially when serial studies are required, and provides only limited information on diastolic function and valve morphology, and so should not be the method of choice. 12 Endomyocardial biopsy has greater sensitivity and specificity for detection and monitoring of the adverse effects of anthracyclines, 5 enabling visualization of loss of myofibrils, vacuolization of cytoplasm, dilatation of the sarcoplasmic reticulum, increased numbers of lysosomes and mitochondrial swelling. 12 However, the invasive nature of the procedure limits its use in clinical practice. Biomarkers have been validated in various studies; they are specific not only in detecting cardiovascular injury but also in determining its extent and reversibility. While troponin T and I are indicators of cardiomyocyte damage, BNP and the N-terminal portion of pro-BNP (NT-proBNP) reflect increased myocardial stress. 13, 14 According to the literature, elevation of troponins is an early indicator of cardiotoxicity, while BNP is less consistent. If the dose of anthracyclines exceeds 240 mg/m 2 , cardiac assessment should be repeated before administering further cycles ( Figure 1 ).
Prevention of cardiotoxicity
Prevention of anthracycline-induced cardiotoxicity, while maintaining the drugs' therapeutic effectiveness, can be achieved by pharmacological and non-pharmacological means.
Non-pharmacological prevention
Cardiovascular risk factors should be identified and treated appropriately as soon as cancer is diagnosed. Patients should be encouraged to adopt a healthy lifestyle, including a diet low in saturated fat and a maximum of 2.5 g of sodium per day, avoid toxic substances such as alcohol and tobacco, and maintain their body mass index close to 25 kg/m 2 . Exercise, whether of low or high intensity, during anthracycline therapy increases cardiovascular reserve 15 and studies in animal models have indicated that it may reduce the cardiotoxic effects of these agents. 16 Although exercise has shown promise in improving cardiopulmonary function in breast cancer survivors, 17, 18 there have been no clinical trials in humans that confirm their cardioprotective role. Another measure is to reduce or avoid the use of drugs that prolong QT interval, particularly 5-hydroxytryptamine 3 antagonists (frequently used to prevent adverse effects of chemotherapy including nausea and vomiting) and antihistamines. 19, 20 It is also important to minimize radiation exposure, to correct electrolyte disturbances and to treat comorbidities ( Table 7) . 21 Decreasing the dose of anthracyclines is another way to reduce the incidence of left ventricular systolic dysfunction (LVSD), as shown by a study of patients taking 400, 500 or 550 mg/m 2 of doxorubicin, in which the incidence of congestive HF was 5%, 16% and 26% respectively. 22 Although anthracyclines appear to be cardiotoxic independently of the dose administered, several studies have shown that continuous infusion of lower doses for between 24 and 92 hours 23 can reduce the severity of cardiac injury, and has been described as an effective way of doing so. 24 Prolonging infusion time reduces cardiotoxicity without compromising the effectiveness of chemotherapy, 25 but infusion lasting longer than 96 hours is associated with a high incidence of stomatitis. The only case in which continuous infusion of doxorubicin appears to have no cardioprotective effect compared to rapid infusion is in children with acute lymphoblastic leukemia (ALL). 26 Other clinical trials using endomyocardial biopsy to assess anthracycline-induced cardiac injury in different drug regimens concluded that continuous perfusion leads to far less significant damage than rapid intravenous administration. 27 These trials also showed that patients receiving continuous infusion had greater tolerance for higher cumulative doses of doxorubicin. Although animal studies demonstrated that anthracycline levels in tumor tissue were the same however the drugs were administered (continuous or rapid infusion), this was not true of cardiac tissue, in which rapid infusion led to higher concentrations and thus greater toxicity. 28
Pharmacological prevention Antioxidants
Although antioxidants neutralize free radicals formed by anthracycline therapy and thus theoretically reduce or prevent cardiotoxicity, clinical trials of N-acetylcysteine, coenzyme Q, L-carnitine, phenethylamines, amifostine and a combination of vitamins E and C and N-acetylcysteine did not show a cardioprotective effect. 29 Erythropoietin and iloprost 30 have been shown to protect against the cardiotoxic effects of doxorubicin in vitro, without affecting its anticancer effectiveness, but their cardioprotective ability will have to be demonstrated in vivo.
Liposomal formulations
One way to combat the adverse cardiac effects of anthracyclines is to change the formulation of the drugs such as encapsulating them in liposomes. 31 Studies comparing unencapsulated and liposome-encapsulated doxorubicin found no difference in anti-tumor response rate, overall survival or progression-free survival, but the incidence of HF and LVSD was lower in patients treated with the liposomal formulation, and this group also had a lower incidence of other adverse effects including neutropenia, nausea, vomiting and diarrhea. 32 Due to their high cost, these formulations are not widely used and the US Food and Drug Administration (FDA) has approved their use only for ovarian cancer, AIDS-related Kaposi's sarcoma, and patients with multiple myeloma who have not responded to a year of treatment with other drugs. 33
Dexrazoxane
Administration of dexrazoxane concomitantly with anticancer regimens can have a cardioprotective effect, preventing elevation of troponins and reducing the incidence of HF. 34 Some authors attribute the cardioprotective effect of this iron chelator to its reduction of the quantity of intracellular iron, which may decrease doxorubicin-induced free radical generation. 34 However, studies on other iron chelators have not demonstrated cardioprotection. 35, 36 It has also been suggested that dexrazoxane's cardioprotective effect is due not only to its antagonizing topoisomerase II cleavage complex formation, but also to its induction of rapid degradation of topoisomerase II beta, which suggests that this enzyme is involved in anthracycline-induced cardiotoxicity. 37 A study of dexrazoxane in over 200 children with ALL showed that it reduced troponin T elevation in both sexes, 38 and limited reduction of fractional shortening and maintained left ventricular thickness-to-dimension ratio at five years, but only in girls. 39 Recently three cases have been reported of adults undergoing chemotherapy combined with dexrazoxane for breast cancer who developed acute myeloid leukemia. However, two studies comparing dexrazoxane with placebo in children with ALL followed for five and 10 years showed no difference in the incidence of secondary malignancy. 40, 41 Nevertheless, in view of its known adverse effects, the FDA and the European Medicines Agency have restricted the use of dexrazoxane to adult patients with advanced or metastatic breast cancer who have already received a cumulative dose of doxorubicin of more than 300 mg/m 2 and who will benefit from additional anthracycline therapy. 42 
Beta-blockers
The cardioprotection afforded by beta-blockers (BBs) appears to derive from their antioxidant and anti-apoptotic properties. One BB, carvedilol, has shown particular promise in reducing the incidence of anthracycline-induced cardiomyopathy and preserving systolic and diastolic function. 43 In children, carvedilol limited troponin I elevation and improved both fractional shortening and peak global systolic strain. 44 According to some studies, BBs and angiotensin-converting enzyme (ACE) inhibitors (see below) can prevent the remodeling associated with HF by reducing adrenergic response. 45, 46 However, no cardioprotective effects have been seen with either metoprolol or enalapril. 47
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers ACE inhibitors and angiotensin receptor blockers (ARBs)
show cardioprotective properties, possibly by reducing oxidative stress, left ventricular remodeling, and apoptosis. 48 When administered for at least two years after discontinuation of chemotherapy in children with anthracycline-induced LVSD, enalapril showed no benefit in terms of reducing left ventricular end-systolic wall stress or preserving fractional shortening. 49 By contrast, in adults treated with high-dose anthracyclines, enalapril prevented HF and worsening of parameters of cardiac function such as LVEF. 50 Studies in angiotensin II type I receptor knockout mice showed that doxorubicin did not have a cardiotoxic effect in these animals and that the administration of ARBs can prevent daunorobucin-induced cardiomyopathy. 48 Although to our knowledge there have been only two randomized trials on ARBs in chemotherapy patients, valsartan was shown to prevent acute prolongation of corrected QT, left ventricular diastolic dilatation and elevation of BNP during one week of chemotherapy, although with no effect on LVEF, 51 and telmisartan prevented reduction in peak strain rate during high-dose anthracycline therapy. 52 Further studies are required with longer follow-up to confirm these effects.
Statins
Statins have antioxidant and anti-inflammatory properties. 53 Studies in animal models demonstrate that fluvastatin mitigates anthracycline-induced cardiotoxicity, reducing oxidative stress and enhancing the expression of the antioxidant enzyme mitochondrial superoxide dismutase 2, resulting in reduced cardiac inflammation. 53 In one clinical trial assessing the effect of continuous statin treatment in patients with breast cancer receiving anthracyclinebased chemotherapy, patients receiving statins had a lower incidence of HF. 54 In another study in patients with previously normal LVEF undergoing anthracycline chemotherapy, LVEF was unchanged at six months in those treated with atorvastatin, compared to a fall of 8% in the control group. 55 Finally, it should be emphasized that there is as yet no solid evidence for the effectiveness of pharmacological prevention of anthracycline-induced cardiomyopathy, and so the main preventive strategy remains thorough prior cardiovascular assessment of patients and appropriate monitoring, selection and adjustment of chemotherapy dosages.
Treatment of heart failure
After the development of signs or symptoms of HF or a reduction in LVEF due to chemotherapy-related cardiotoxicity, treatment should be based on the current guidelines. 56 Although selection of the best therapy is obviously important, one study has shown that the main factor determining successful treatment is the time between the end of chemotherapy and the start of HF therapy, since if this is longer than six months, LVEF is unlikely to recover completely. 57
Prospects for the future
Several clinical trials are currently under way aiming to assess various therapeutic strategies, pharmacological and non-pharmacological, for the prevention of anthracyclineinduced cardiomyopathy (Table 8 ). It will be some years before the results are known, and there is still a pressing need for evidence-based guidelines for the assessment and clinical monitoring of these patients.
Conclusion
The longer survival of patients undergoing anticancer therapy and the consequent increase in the incidence of anthracycline-induced cardiomyopathy mean that it is necessary to investigate and determine the precise mechanisms leading to adverse cardiac effects, in order to prevent them. Further research will enable specific and validated prevention plans to be established.
